Turning The Dial Up On Digital

The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.

The reasons driving alliances and deals between pharma and digital health have been well documented; the need for innovation without internal capability, the need to remain commercially competitive through the addition of data and analytics, the weight of evidence to prove value to regulators and payers, and the evolution into patient-centric organizations through new forms of engagement.

Indeed, some companies are investing in complete internal digital transformation to become value-driven innovators. In December, Japanese pharma major Astellas Pharma, Inc. detailed its digital transformation strategy, which it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bringing Israeli Medical Device Candidates To The Right Partners In The US

15 May 2025

• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

14 May 2025

• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

13 May 2025

• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

07 May 2025

• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

20 May 2025

• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.